20 Recruiting Neuroblastoma Phase 1 Clinical Trials
Active phase 1 studies for neuroblastoma enrolling across the USA. Verify eligibility and contact site coordinators.
All Neuroblastoma studiesPhase 1 Studies for Neuroblastoma
A Study of N9 Chemotherapy in Children With Neuroblastoma
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
📍 UCSF Medical Center at Mission Bay — San Francisco, California
View Study & Checklist ➔3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN
📍 Houston Methodist Hospital — Houston, Texas
View Study & Checklist ➔Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma
📍 Texas Children's Hospital — Houston, Texas
View Study & Checklist ➔Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed/Refractory Neuroblastoma
📍 University of Wisconsin Carbone Cancer Center; UW Hospital and Clinics; American Family Children's Hospital — Madison, Wisconsin
View Study & Checklist ➔Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma
📍 Children's Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
📍 Children's Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
📍 Seattle Children's Hospital — Seattle, Washington
View Study & Checklist ➔18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma
📍 St. Jude Children's Research Hospital — Memphis, Tennessee
View Study & Checklist ➔Rapid Administration Pilot for Infusing Dinutuximab
📍 Childrens Hospital Los Angeles — Los Angeles, California
View Study & Checklist ➔Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma
📍 Memorial Sloan Kettering Cancer Center — New York, New York
View Study & Checklist ➔Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma
📍 Texas Children's Hospital — Houston, Texas
View Study & Checklist ➔Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy
📍 University of Florida — Gainesville, Florida
View Study & Checklist ➔Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
📍 Boston Children's Hospital — Boston, Massachusetts
View Study & Checklist ➔Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
📍 Emory - Winship Cancer Institute — Atlanta, Georgia
View Study & Checklist ➔Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
📍 University of Florida — Gainesville, Florida
View Study & Checklist ➔Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
📍 University of Alabama/Children's of Alabama — Birmingham, Alabama
View Study & Checklist ➔Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
📍 Children's Healthcare of Atlanta — Atlanta, Georgia
View Study & Checklist ➔